Skip to main content
Premium Trial:

Request an Annual Quote

As Incyte Predicts Weaker Year, Stock Falls Sharply

NEW YORK, Sept. 4-Citing slowdowns in database subscriptions and licensing deals, Incyte Genomics today downgraded its financial outlook for the remainder of the fiscal year.


The company said today that it expects its net losses for the year to fall between $75 million to $98 million, considerably more than the $65 million to $85 million loss estimate that Incyte previously announced.


Incyte's revenue guidance for the fiscal year now falls between $100 million and $130 million, down from the $130 million to $150 million range.


Shares of the company were trading at $4.36 Wednesday morning, down more than 22 percent from yesterday's close of $5.63.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.